# Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

> **NCT00003827** · PHASE2 · UNKNOWN · sponsor: **ALZA** · enrollment: 25 (estimated)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** cytarabine
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003827
- **Lead sponsor:** ALZA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1999-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003827, "Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*